Vitamin D sufficiency linked to better pancreatic cancer survival

By Shreeya Nanda

Survival is improved in pancreatic cancer patients with sufficient versus deficient plasma levels of 25-hydroxyvitamin D [25(OH)D], as assessed prior to diagnosis.

These findings indicate that "prediagnostic plasma 25(OH)D is a prognostic factor in patients with pancreatic cancer", say researchers whose study population was drawn from five prospective US cohorts, including the Health Professionals Follow-up Study and the Nurses' Health Study.

Among 493 patients diagnosed between 1984 and 2008, those with sufficient (≥30 ng/mL) and relatively insufficient (20 to <30 ng/mL) 25(OH)D levels had a significant 34% and 21% reduced risk of death, respectively, relative to participants who were vitamin D deficient (<20 ng/mL).

The results "remained largely unchanged" after adjusting for various confounders, such as time between blood draw and diagnosis, history of diabetes and body mass index, the team reports in the Journal Of Clinical Oncology.

Researcher Brian Wolpin (Dana-Farber Cancer Institute, Boston, Massachusetts, USA) and colleagues conclude: "When considering these findings together with previously reported preclinical data in pancreatic cancer models, agonists of the vitamin D receptor are a potentially attractive therapeutic approach for investigation in this highly lethal malignancy."

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Space-based research uncovers key to cancer cell survival